Delabar Jean M, Ortner Marion, Simon Stephanie, Wijkhuisen Anne, Feraudet-Tarisse Cecile, Pegon Jonathan, Vidal Emma, Hirschberg Yael, Dubois Bruno, Potier Marie-Claude
INSERM U 1127, CNRS UMR 7225 UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et la Moelle épinière, ICM Sorbonne Universités Paris France.
Brain & Spine Institute (ICM) CNRS UMR7225 INSERM UMRS 975 Paris France.
Alzheimers Dement (N Y). 2020 Jul 2;6(1):e12046. doi: 10.1002/trc2.12046. eCollection 2020.
An effective therapy has not yet been developed for Alzheimer's disease (AD), in part because pathological changes occur years before clinical symptoms manifest. We recently showed that decreased plasma DYRK1A identifies individuals with mild cognitive impairment (MCI) or AD, and that aged mice have higher DYRK1A levels.
We assessed DYRK1A in plasma in young/aged controls and in elderly cognitive complainers with low (L) and high (H) brain amyloid load.
DYRK1A level increases with age in humans. However, plasma from elderly individuals reporting cognitive complaints showed that the H group had the same DYRK1A level as young adults, suggesting that the age-associated DYRK1A increase is blocked in this group. L and H groups had similar levels of clusterin.
These results are reflective of early changes in the brain. These observations suggest that plasma DYRK1A and not clusterin could be used to classify elderly memory complainers for risk for amyloid beta pathology.
尚未开发出针对阿尔茨海默病（AD）的有效疗法，部分原因是病理变化在临床症状出现前数年就已发生。我们最近发现，血浆中双特异性酪氨酸磷酸化调节激酶1A（DYRK1A）水平降低可识别轻度认知障碍（MCI）或AD患者，且老年小鼠的DYRK1A水平更高。
我们评估了年轻/老年对照以及脑淀粉样蛋白负荷低（L）和高（H）的老年认知主诉者血浆中的DYRK1A。
人类血浆中DYRK1A水平随年龄增长而升高。然而，有认知主诉的老年人血浆显示，H组的DYRK1A水平与年轻人相同，这表明该组中与年龄相关的DYRK1A升高受到了抑制。L组和H组的簇集蛋白水平相似。
这些结果反映了大脑的早期变化。这些观察结果表明，血浆中的DYRK1A而非簇集蛋白可用于对有记忆主诉的老年人进行淀粉样β蛋白病理风险分类。
